pyridostigmine bromide has been researched along with fingolimod hydrochloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eadie, M; Hollingworth, S; Page, A; Walker, K | 1 |
| Carreras, I; Dedeoglu, A; Jung, Y; Lopez-Benitez, J; Tognoni, CM | 1 |
2 other study(ies) available for pyridostigmine bromide and fingolimod hydrochloride
| Article | Year |
|---|---|
Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Australia; Drug Prescriptions; Fingolimod Hydrochloride; Geography; Humans; Immunologic Factors; Interferon-beta; Linear Models; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroprotective Agents; Pharmacoepidemiology; Prevalence; Propylene Glycols; Pyridostigmine Bromide; Riluzole; Sphingosine | 2013 |
Fingolimod mitigates memory loss in a mouse model of Gulf War Illness amid decreasing the activation of microglia, protein kinase R, and NFκB.
Topics: Amnesia; Animals; Disease Models, Animal; Fingolimod Hydrochloride; Gulf War; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Microglia; Neuroinflammatory Diseases; NF-kappa B; Persian Gulf Syndrome; Protein Kinases; Pyridostigmine Bromide | 2023 |